Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Ariel Denson, PharmD, Kristyn Y. DiSogra, PharmD, BCOP, Justin Arnall, PharmD, BCOP, Srinivasa R. Sanikommu, MD, Nilay A. Shah, MD, Brittany K. Ragon, MD, Thomas G. Knight, MD, Jing Ai, MDPhD, Michael R. Grunwald, MD, Belinda R Avalos, MD, Edward A Copelan, Aleksander L. Chojecki, MD

Blood (2020) 136 (Supplement 1): 14–17.

https://doi.org/10.1182/blood-2020-137250

Published: 2020

Journal Articles

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Heather Cranford, CPhT, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136578

Published: 2020

Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139898

Published: 2020

Journal Articles

Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study

Michael R. Grunwald, MD, Ivy Altomare, MD, Robyn M. Scherber, MD, Patricia Kalafut, PhD, Haobo Ren, PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-134841

Published: 2020

Journal Articles

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Siddharth Jayant Kunte, MD, Lisa Rybicki, MS, Auro Viswabandya, MD, Asad Bashey, MD PhD, Madiha Iqbal, MBBS, Michael R. Grunwald, MD, Bhagirathbhai Dholaria, MBBS, Hany Elmariah, MDMS, Michael Ozga, MD, Anurag K. Singh, MD, Sameem Abedin, MD, Vikas Gupta, MD FRCP, FRCPath, Amy E. DeZern, MD, Richard J. Jones, MD, Aaron T. Gerds, MDMS, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136622

Published: 2020

Journal Articles

Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Issam S. Hamadeh, PharmD, Michael R. Grunwald, MD, Allison Martin, PharmD, Jai N. Patel, PharmD, Alexandra Shillingburg, PharmD, Ekaterina Kachur, PharmD, Allene COOK, PharmD, Allison Karabinos, PharmD, Jing Ai, MDPhD, Thomas G. Knight, MD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, Belinda R Avalos, MD, Edward A Copelan, Zainab Shahid, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141124

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137222

Published: 2020

Journal Articles

Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative

Aleksander L. Chojecki, MD, Kristyn Y. DiSogra, PharmD, BCOP, Justin Arnall, PharmD, BCOP, Nicole Cowgill, PharmD, CSP, Srinivasa Reddy Sanikommu, MD, Nilay A. Shah, MD, Charles H. Packman, MD, Brittany K. Ragon, MD, Thomas G. Knight, MD, Jing Ai, MDPhD, Belinda R Avalos, MD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136319

Published: 2020

Journal Articles

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Jeffrey I. Zwicker, MD, David S. Lessen, MD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 168.

https://doi.org/10.1182/blood-2019-123835

Published: 2019

Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 3907.

https://doi.org/10.1182/blood-2019-124741

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Thomas G. Knight, MD, Myra Robinson, MS, Jing Ai, MD PhD, Brittany K Ragon, MD, Rhonda Davis, RN, BSN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Hailey Glover, RN, BSN, Jigar Trivedi, MSc, PharmD, Belinda R Avalos, MD, Jonathan M. Gerber, MD, James T Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 2099.

https://doi.org/10.1182/blood-2019-128858

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Chamikara Paranagama, PhD, Jill Kaufman, Jessica Chung, PhD MPH, Michael R. Grunwald, MD, Philomena Colucci, DO, MS, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2018-99-115294

Published: 2018

Journal Articles

Survival and Time to Response with Frontline Hypomethylating Agents in AML

Jing Ai, MD, Danielle Boselli, MS, Lauren M. Bohannon, Thomas G. Knight, MD, Brittany Ragon, MD, Belinda Rene Avalos, MD, Edward A. Copelan, MD, James T Symanowski, PhD, Jonathan M. Gerber, MD, Michael R. Grunwald, MD

Blood (2018) 132 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2018-99-119463

Published: 2018

Journal Articles

Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation

Srinivasa Reddy Sanikommu, MD, Olivia Copelan, BA, Jiaxian He, MS, Candace M. Butler, MSPH, Michael R. Grunwald, MD, Nilanjan Ghosh, MD PhD, Jing Ai, MD, Thomas G. Knight, MD, Brittany Ragon, MD, Ryan Jacobs, MD, Bei Hu, Saad Z. Usmani, MD, James T Symanowski, PhD, Zainab Shahid, MD

Blood (2018) 132 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2018-99-119612

Published: 2018

Journal Articles

Patient Reported Financial Toxicity in Acute Leukemia

Thomas G. Knight, MD, Myra Robinson, MS, Michael R. Grunwald, MD, Lauren M. Bohannon, Erin Blackwell, RN, BSN, OCN, Jing Ai, MD, Brittany Ragon, MD, Rhonda Davis, BSN, RN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Jigar Trivedi, MSc, PharmD, Justin Arnall, PharmD, CPP, BCOP, Belinda Rene Avalos, MD, James T Symanowski, PhD, Edward A. Copelan, MD, Jonathan M. Gerber, MD

Blood (2018) 132 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2018-99-119163

Published: 2018

Journal Articles

De-Escalation of Antimicrobials in Adult Hematopoietic Cell Transplantation Recipients with Febrile Neutropenia of Unknown Origin

Megan M. Petteys, PharmD, Ekaterina Kachur, PharmD, Kelly E. Pillinger, PharmD, Jiaxian He, MS, James T. Symanowski, PhD, Candace M. Butler, MSPH, Lynn S. Sanders, MSN, RN, OCN, Nilanjan Ghosh, MD PhD, Michael R. Grunwald, MD, Belinda Rene Avalos, MD, Saad Z. Usmani, MD, Edward A. Copelan, MD, Zainab Shahid, MD

Blood (2018) 132 (Supplement 1): 2079.

https://doi.org/10.1182/blood-2018-99-117148

Published: 2018

Journal Articles

A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia

Jonathan M. Gerber, MD, Lawrence J. Druhan, PhD, David Foureau, PhD, Elizabeth Jandrisevits, Amanda Lance, BS, Andrea E. Price, BS, Virginia Thurston, PhD, Jing Ai, MD PhD, Michael R. Grunwald, MD, Edward H. Lipford, MD, Belinda R. Avalos, MD

Blood (2016) 128 (22): 2912.

https://doi.org/10.1182/blood.V128.22.2912.2912

Published: 2016

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

NARROW

Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Survival and Time to Response with Frontline Hypomethylating Agents in AML

Higher Incidence of Hemorrhagic Cystitis after Haploidentical Compared to Matched Sibling Donor Transplantation

Patient Reported Financial Toxicity in Acute Leukemia

De-Escalation of Antimicrobials in Adult Hematopoietic Cell Transplantation Recipients with Febrile Neutropenia of Unknown Origin

A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only